“Blind spots of insurance benefits on hepatitis C therapies, Sovaldi & Harvoni, will be resolved”

The hepatitis C treatment, ‘Harvoni(ledipasvir+sofosbuvir),’ will also be applied for the health insurance benefit even if the Dak-Sun combination therapy cannot be used.

Side effects which has been indicated as blind spots of the Harvoni’s insurance benefit application were also included, such as uncompensated liver cirrhosis and post-liver-transplant recurrence.

Moreover, the application ra...